Two South Korean companies Macrogen and Bigster have announced a partnership. In an unexpected turn of events, the news that the development team also includes specialists from North Korea. Previously, there were not many joint projects of the two countries in the scientific community..
The joint efforts will focus on the development of a blockchain platform that will facilitate the transfer and storage of genome data. Through this platform, organizations hope to offer a safe and sustainable method of handling genetic information. Macrogen believes that the human genome — it is one of the most important research topics in health care.
Individual genome data can enable physicians to improve their work efficiency (in particular, diagnostics) and improve the techniques of treating their patients. Also, work in this area will allow pharmaceutical companies to develop new drugs and therapeutic drugs..
Although genetic information is widely used in health care, its confidential nature, including details such as the biological characteristics of individuals, requires special conditions for the storage and transmission of data. Macrogen claims that they need cryptographic and non-cryptographic methods of protection against hacking in order to work. Confidentiality risks are assigned a special role.
Working on the basis of blockchain, based on decentralization and distribution of data will eliminate the risks of accidental changes or hacking of genetic information. Given the confidential nature of such data, the biotech company decided to use a consortium a model whereby participation in the blockchain is limited to key parties such as pharmaceutical companies, research organizations, genomic analysis groups, and hospitals. The Seoul firm believes this model will be easy to expand for further management..
We’ve previously written about how nuclear medicine can help fight diabetes..
text: Evgeniya Likhodey, photo: Bloomberg
South Korea to create blockchain-driven free trade zone